// App-Quantinova.ai

TPS4161 : A randomized phase II trial of niraparib plus either nivolumab or ipilimumab in patients with advanced pancreatic cancer whose cancer has not progressed on platinum-based therapy.

Researchers

Presenter

  • Kim Anna Reiss

Principal Investigators

  • Rosemarie Mick

  • Mark H. O'Hara

  • Ursina R. Teitelbaum

  • Thomas Benjamin Karasic

  • Charles John Schneider

  • Peter J. O'Dwyer

  • Danielle Karlson

  • Stacy Cowden

  • Mary Jane Fuhrer

  • Erica L. Carpenter

  • Austin A Pantel

  • Mehran Makvandi

  • David A. Mankoff

  • Katharine Nathanson

  • Kara Noelle Maxwell

  • Gregory Lawrence Beatty

  • Susan M. Domchek

Medical Centers

  • University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA

  • University of Pennsylvania, Philadelphia, PA

  • University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

  • University of Pennsylvania Abramson Cancer Center, Division of Medical Oncology, Philadelphia, PA

  • University of Pennsylvania, Philadelphia, PA

  • Hospital of the University of Pennsylvania, Philadelphia, PA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Peripheral blood mononuclear cell

  • Circulating tumor cells

  • Circulating DNA

Drug/Treatment

  • Ipilimumab

  • Niraparib

  • Nivolumab

Outcome

  • N/A

Study Design

  • Randomized

  • Adaptive

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved